US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Praxis Precision Medicines, Inc. - Common Stock
(NQ:
PRAX
)
285.93
-2.69 (-0.93%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Praxis Precision Medicines, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Praxis Precision Medicines (NASDAQ:PRAX) Reports Q4 2025 Results Amid Key Regulatory Milestones
↗
February 19, 2026
Via
Chartmill
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
February 19, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites
↗
February 17, 2026
Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.
Via
Stocktwits
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress
↗
February 14, 2026
Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.
Via
The Motley Fool
Topics
Regulatory Compliance
Soleus Adds a Significant Number of Celcuity Shares
↗
February 13, 2026
This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.
Via
The Motley Fool
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
February 09, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
January 22, 2026
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Initial Public Offering
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
January 13, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
January 12, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 09, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
January 08, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
January 06, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
January 06, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Why Praxis Precision Medicines Stock Popped Today
↗
December 29, 2025
A medical breakthrough is shining a light on the biotech's promising development platform.
Via
The Motley Fool
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
December 29, 2025
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...
Via
MarketMinute
Topics
ETFs
Intellectual Property
Praxis Stock Surges On FDA Breakthrough Status For Essential Tremor Drug
↗
December 29, 2025
Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor.
Via
Benzinga
Traders are paying attention to the gapping stocks in Monday's session.
↗
December 29, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
Via
Chartmill
Why Did Praxis Precision Stock Surge 12% Pre-Market Today?
↗
December 29, 2025
The Breakthrough Therapy Designation designation for ulixacaltamide was granted after positive topline results from the Essential3 program, which included two Phase 3 studies.
Via
Stocktwits
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
December 29, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
December 11, 2025
EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
December 09, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
December 08, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
What's going on in today's session
↗
December 05, 2025
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
Top movers analysis in the middle of the day on 2025-12-05: top gainers and losers in today's session.
↗
December 05, 2025
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
Via
Chartmill
The market is filled with gapping stocks in Friday's session.
↗
December 05, 2025
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.
Via
Chartmill
What's going on in today's pre-market session
↗
December 05, 2025
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via
Chartmill
Why Did PRAX Stock Rocket 24% Pre-Market Today?
↗
December 05, 2025
The Data Monitoring Committee (DMC) recommended stopping the EMBOLD study ahead of schedule after the interim analysis demonstrated strong positive outcomes.
Via
Stocktwits
Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What's Going On?
↗
December 05, 2025
Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10— what's going on?
Via
Benzinga
Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar
↗
December 05, 2025
Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.
Via
Stocktwits
Topics
Artificial Intelligence
ETFs
Economy
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
